Phase 1 clinical trials are often seen as a last resort with little therapeutic promise, but a new retrospective study challenges that perception. Researchers at two NCI-Designated Comprehensive Cancer Centers analyzed outcomes for 335 patients with gynecologic cancers enrolled in phase 1 trials between 2000 and 2022 — and the results were encouraging.

More than half of response-evaluable patients (56.2%) experienced clinical benefit, mostly through stable disease. Median overall survival was 1.16 years, comparable to outcomes seen in similarly pretreated patients outside of trials — meaning enrollment wasn't harmful. Notably, survival outcomes improved dramatically over time, likely reflecting better supportive care and the rise of immunotherapy.

By the Numbers:

• 335 patients enrolled across ovarian (55.5%), uterine (25.4%), cervical (15.2%), and other gynecologic cancers
• 56.2% of response-evaluable patients experienced clinical benefit
• 5-year overall survival rate: 9.1%
• Median survival rose from 1 year (2000–2006) to 2.17 years (2015–2022)
• Non-Hispanic Black patients had a higher mortality risk (HR 1.56), though all racial groups derived equal clinical benefit

Why it matters: For oncologists treating patients who've exhausted standard options, this study reinforces that phase 1 trial referral is a legitimate and potentially beneficial pathway. The authors also emphasize that race and ethnicity should never be a barrier to trial enrollment.